To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:7 Issue:10 Number:43 ISSN#:2564-2537
ACE Report #10382
Ace Report Cover Cannabis

Dronabinol does not cause metabolic disturbances in managing chronic neuropathy pain

How to Cite

OrthoEvidence. Dronabinol does not cause metabolic disturbances in managing chronic neuropathy pain. ACE Report. 2018;7(10):43. Available from:

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

A 4-week pilot study with the cannabinoid receptor agonist dronabinol and its effect on metabolic parameters in a randomized trial

Clin Ther. 2015 Oct 1;37(10):2267-74. doi: 10.1016/j.clinthera.2015.07.023

Contributing Authors:
L Bayman J Valestin A Rizvi-Toner R Schey ZW Reichenbach J Sloan

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


13 patients diagnosed with non-cardiac chest pain were randomly assigned to orally consume twice a day for 4 weeks either 5mg dronabinol capsules or placebo capsules. Metabolic parameters such as body mass index, various cholesterol levels, triglyceride level, plasma glucose level, insulin and leptin level, and high-sensitivity C-reactive protein level were assessed at the beginning and end of the...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.